Education
About Us
Working with TipRanks
Follow Us
Kenvue, Inc. (KVUE)
NYSE:KVUE
KVUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.75 - $25.17
Previous CloseN/A
Volume2.33M
Average Volume (3M)16.57M
Market Cap
$39.74B
Enterprise Value$47.93B
Total Cash (Recent Filing)$1.07B
Total Debt (Recent Filing)$8.74B
Price to Earnings (P/E)28.1
Beta0.31
Next Earnings
Oct 23, 2025EPS Estimate
0.27Last Dividend Ex-Date
Aug 13, 2025Dividend Yield3.97%
Share Statistics
EPS (TTM)0.29
Shares Outstanding1,919,070,000
10 Day Avg. Volume12,118,902
30 Day Avg. Volume16,570,964
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue3.17
Enterprise Value/Gross Profit5.46
Enterprise Value/Ebitda15.78
Forecast
1Y Price Target
$23.64Price Target Upside14.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Brand PortfolioKenvue’s diversified portfolio of leading consumer healthcare brands holds potential for stable and profitable growth.
Leadership And StrategyThe appointment of Mr. Kirk Perry as interim CEO indicates a commitment to conducting a comprehensive search for the company’s next permanent CEO, following the replacement of both the CEO and CFO.
Strategic ReviewThe review of strategic alternatives announced by KVUE could lead to portfolio simplification, which may enhance operating performance to accelerate profitable growth.
Bears Say
Earnings And Financial PerformancePreliminary Q2 sales and earnings results were below expectations, with organic sales at -4.2% compared to the Street’s -1% prior.
Product Segment WeaknessWeakness in Q2 is expected to be driven by the skin health & beauty segment, where weak volumes are likely to persist due to soft sales in sun care and greater pricing investments.
Sales PerformanceSales were below plan, and guidance has been lowered to account for slower category growth rates and soft seasonal business.
Kenvue, Inc. News
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $19.75 and its highest was $25.17 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $39.74B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is Oct 23, 2025 which is in 50 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on Jul 14, 2025. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.282 by $0.008.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Quarterly dividend of $0.207 which represents an annual dividend yield of 3.97%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 0.27.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,919,070,000 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.29 in its last earnings report, beating expectations of $0.282. Following the earnings report the stock price went up 2.223%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
Kenvue, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.64 (14.15% Upside)
$23.64 (14.15% Upside)
Blogger Sentiment
Bullish
KVUE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 32.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.21%
12-Months-Change
Fundamentals
Return on Equity
13.56%
Trailing 12-Months
Asset Growth
2.61%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
KVUE Company Deck
KVUE Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted Kenvue's strengths in market share gains and leadership improvements but was overshadowed by underwhelming financial performance and challenges in key markets. The revised guidance and focus on strategic alternatives suggest a period of transition and uncertainty.View all KVUE earnings summariesKVUE Revenue Breakdown
42.23% Self Care
30.33% Essential Health
27.43% Skin Health and Beauty
KVUE Stock 12 Month Forecast
Average Price Target
$23.64
▲(14.15% Upside)
Technical Analysis
Ownership Overview
1.13% Insiders
35.16% Mutual Funds
17.26% Other Institutional Investors
19.25% Public Companies and Individual Investors